ANRO
Alto Neuroscience, Inc.
Biotechnology
Market Cap$753M
5Y Perf.+39.4%
Build Your Comparison
Side-by-side financial analysisANRO
SAVA
ACAD
PRAX
Try popular comparisons:
Stock Comparison
ANRO vs SAVA vs ACAD vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$64M
5Y Perf.-30.5%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.61B
5Y Perf.-9.3%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$7.70B
5Y Perf.+469.8%
ANRO vs SAVA vs ACAD vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ANRO |  SAVA |  ACAD |  PRAX |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $753M | $64M | $3.61B | $7.70B |
| Revenue (TTM) | $0.00 | $0.00 | $1.10B | $0.00 |
| Net Income (TTM) | $-74M | $-106M | $376M | $-327M |
| Gross Margin | — | — | 91.5% | — |
| Operating Margin | — | — | 7.4% | — |
| Forward P/E | — | — | 54.2x | — |
| Total Debt | $4M | $0.00 | $52M | $110K |
| Cash & Equiv. | $176M | $129M | $178M | $357M |
ANRO vs SAVA vs ACAD vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANRO
SAVA
ACAD
PRAX
| Stock | Feb 24 | Jun 26 | Return |
|---|---|---|---|
| Alto Neuroscience, … (ANRO) | 100 | 139.4 | +39.4% |
| Cassava Sciences, I… (SAVA) | 100 | 69.5 | -30.5% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 90.7 | -9.3% |
| Praxis Precision Me… (PRAX) | 100 | 569.8 | +469.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANRO vs SAVA vs ACAD vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Alto Neuroscience, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ACAD emerged as the overall leader. Track its performance:
ANRO
Alto Neuroscience, Inc.
The Long-Run Compounder
ANRO is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 3.7% 10Y total return vs PRAX's -36.1%
- +7.8% vs SAVA's -37.7%
Best for: long-term compounding
SAVA
Cassava Sciences, Inc.
The Specific-Use Pick
SAVA plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.10
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- Beta 1.10, current ratio 3.83x
- 11.9% revenue growth vs SAVA's -5.4%
Best for: income & stability and growth exposure
PRAX
Praxis Precision Medicines, Inc.
The Defensive Pick
PRAX is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ACAD | 11.9% revenue growth vs SAVA's -5.4% |
| Quality / Margins | ACAD | 34.3% margin vs ANRO's 2.2% |
| Stability / Safety | ACAD | Beta 1.10 vs ANRO's 2.60 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  ANRO | +7.8% vs SAVA's -37.7% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs SAVA's -75.3%, ROIC 10.0% vs -6.3% |
ANRO vs SAVA vs ACAD vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2018
FY 2024
ANRO vs SAVA vs ACAD vs PRAX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGPRAX
Who Leads Where
ACAD leads in 2 of 6 categories
SAVA leads 1 • ANRO leads 1 • PRAX leads 0 • 1 tied
Explore the data ↓PRAXPraxis Precision Medi…
0leads
SAVACassava Sciences, Inc.
1leads
ANROAlto Neuroscience, In…
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs ANROvs SAVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ANRO4/6
Risk & VolatilityBeta, volatility, and downside exposure
ACAD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACAD and PRAX operate at a comparable scale, with $1.1B and $0 in trailing revenue.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… |  PRAXPraxis Precision … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $1.1B | $0 |
| EBITDAEarnings before interest/tax | $56M | -$110M | $96M | -$357M |
| Net IncomeAfter-tax profit | -$74M | -$106M | $376M | -$327M |
| Free Cash FlowCash after capex | -$63M | -$84M | $212M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | — | +91.5% | — |
| Operating MarginEBIT ÷ Revenue | — | — | +7.4% | — |
| Net MarginNet income ÷ Revenue | — | — | +34.3% | — |
| FCF MarginFCF ÷ Revenue | — | — | +19.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +9.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -42.9% | +62.1% | -81.8% | +2.7% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — SAVA and PRAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Market CapShares × price | $753M | $64M | $3.6B | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $581M | -$65M | $3.5B | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -9.80x | -2.54x | 9.21x | -19.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 54.20x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 25.09x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 3.37x | — |
| Price / BookPrice ÷ Book value/share | 4.10x | 0.42x | 2.94x | 6.83x |
| Price / FCFMarket cap ÷ FCF | — | — | 34.34x | — |
Evenly matched — SAVA and PRAX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-96 for SAVA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs SAVA's 2/9, reflecting solid financial health.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -47.2% | -95.8% | +35.6% | -43.0% |
| ROA (TTM)Return on assets | -38.8% | -75.3% | +26.2% | -40.2% |
| ROICReturn on invested capital | — | -6.3% | +10.0% | -65.0% |
| ROCEReturn on capital employed | -38.9% | -99.9% | +10.1% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.03x | — | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | -$172M | -$129M | -$126M | -$357M |
| Cash & Equiv.Liquid assets | $176M | $129M | $178M | $357M |
| Total DebtShort + long-term debt | $4M | $0 | $52M | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | -30.35x | — | — | — |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ANRO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANRO five years ago would be worth $10,372 today (with dividends reinvested), compared to $1,219 for SAVA. Over the past 12 months, ANRO leads with a +776.3% total return vs SAVA's -37.7%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs SAVA's -27.9% — a key indicator of consistent wealth creation.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +29.4% | -36.8% | -19.3% | -6.9% |
| 1-Year ReturnPast 12 months | +776.3% | -37.7% | -3.0% | +491.9% |
| 3-Year ReturnCumulative with dividends | +3.7% | -62.5% | -14.3% | +1757.4% |
| 5-Year ReturnCumulative with dividends | +3.7% | -87.8% | -22.6% | -14.2% |
| 10-Year ReturnCumulative with dividends | +3.7% | -38.0% | -44.6% | -36.1% |
| CAGR (3Y)Annualised 3-year return | +1.2% | -27.9% | -5.0% | +164.8% |
ANRO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ACAD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than ANRO's 2.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 75.8% from its 52-week high vs SAVA's 26.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.60x | 1.92x | 1.10x | 1.55x |
| 52-Week HighHighest price in past year | $28.44 | $4.98 | $27.81 | $366.52 |
| 52-Week LowLowest price in past year | $2.15 | $1.27 | $19.69 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +26.5% | +75.8% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 42.7 | 47.9 | 31.9 |
| Avg Volume (50D)Average daily shares traded | 316K | 134K | 1.4M | 396K |
ACAD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ANRO as "Buy", SAVA as "Buy", ACAD as "Buy", PRAX as "Buy". Consensus price targets imply 127.8% upside for PRAX (target: $607) vs 61.2% for ANRO (target: $35).
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $34.60 | — | $34.78 | $607.15 |
| # AnalystsCovering analysts | 8 | 12 | 37 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). SAVA leads in 1 (Income & Cash Flow). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
ANRO vs SAVA vs ACAD vs PRAX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ANRO or SAVA or ACAD or PRAX a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate Alto Neuroscience, Inc. (ANRO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANRO or SAVA or ACAD or PRAX?
Over the past 5 years, Alto Neuroscience, Inc.
(ANRO) delivered a total return of +3. 7%, compared to -87. 8% for Cassava Sciences, Inc. (SAVA). Over 10 years, the gap is even starker: ANRO returned +3. 7% versus ACAD's -44. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANRO or SAVA or ACAD or PRAX?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 10β versus Alto Neuroscience, Inc. 's 2. 60β — meaning ANRO is approximately 136% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ANRO or SAVA or ACAD or PRAX?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANRO or SAVA or ACAD or PRAX?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ANRO or SAVA or ACAD or PRAX more undervalued right now?
Analyst consensus price targets imply the most upside for PRAX: 127.
8% to $607. 15.
07Which pays a better dividend — ANRO or SAVA or ACAD or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ANRO or SAVA or ACAD or PRAX better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Alto Neuroscience, Inc. (ANRO) carries a higher beta of 2. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -44. 6%, ANRO: +3. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ANRO and SAVA and ACAD and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ANRO is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.